Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederendpts.com
ENDPOINTS NEWS
Get the latest updates from ENDPOINTS NEWS directly as they happen.
Follow now 182 followers
Latest posts
Last updated 2 months ago
#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remain
2 months ago
CHICAGO — As part of a hormone therapy regimen for prostate cancer...
Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront
2 months ago
Eli Lilly, which has made billions off the success of its GLP-1...
#ASCO26: AstraZeneca's triplet combo succeeds in liver cancer subgroup
2 months ago
CHICAGO — AstraZeneca on Monday reported data from a new study showing...
Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets
2 months ago
Servier will pick up the muscular dystrophy business from Edgewise Therapeutics for...
Turn Therapeutics' eczema drug shows rapid response in mid-stage data
2 months ago
California biotech Turn Therapeutics shared Phase 2 data for its topical atopic...
After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing
2 months ago
Avenzo Therapeutics, one of the first biotechs to get major Western VC...
#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update
2 months ago
CHICAGO — Eli Lilly in April signed an up to $7 billion...
Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines
2 months ago
🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million...
#ASCO26: Lilly's plenaries; Incyte's frontline data in lymphoma
2 months ago
Two plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial...
Shionogi wins US approval for first pill to prevent Covid following exposure
2 months ago
Japan's Shionogi on Monday said it won FDA approval for its oral...
Epigenetic editing shows promise against chronic hep B infections
2 months ago
A new method of CRISPR-based gene editing shows promise in curtailing chronic...
The cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way
2 months ago
How much is a regulatory shortcut worth The cost of a priority...